The best way to develop innovative therapies is through openness and collaboration. That’s why MVA member SmiLe Venture Hub and MVA member Servier/Symphogen have partnered in the Golden Ticket program to support the next generation of biotech pioneers in turning bold ideas into real solutions that make a difference for patients.
The Servier Golden Ticket is a unique opportunity providing a promising early-stage company with the resources and support needed to accelerate their research in oncology, neuroscience, and platform technologies, including AI/ML-driven drug design.
What’s included in the Servier Golden Ticket?
- A dedicated lab bench & office space at SmiLe Venture Hub in Lund
- Access to state-of-the-art facilities and equipment
- Mentorship & business coaching from SmiLe
- Direct engagement with Servier’s scientific & industry advisors
- Exclusive access to the SmiLe’s & Servier’s networks throughout the year
Deadline for applications is May 1st 2025. Visit SmiLe Venture Hub to learn more about how to apply for the Servier Golden Ticket